RSS

nanobody drug

Ablynx has completed target enrolment of a phase I/IIa safety study of its anti-RSV nanobody, ALX-0171 for the treatment of respiratory syncytial virus (RSV) infection in infants more

News

Ablynx and Novo Nordisk will collaborate to discover and develop multi-specific nanobody drug candidates with an option to expand the agreement to include a second nanobody programme more

News